The aim is to study the changes in Galectin-3 & RANKL during disease transition from asymptomatic smouldering myeloma to clinically aggressive symptomatic myeloma to identify ‘markers’ that predict disease progression
|Effective start/end date||2/10/23 → 2/10/24|
- University of Northampton (lead)
- University of Liverpool
- Science and Technology, University of Northampton
- Department of Haematology Peterborough City Hospital
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.